Loading patent…
AssigneeAscendis Pharma Oncology Division A/S
InventorsDavid B. ROSEN, Luis ZUNIGA, Juha PUNNONEN, Lars HOLTEN-ANDERSEN, Kennett SPROGØE, Yang YANG-MALTEN, Torben LESSMANN, Nicola BISEK, Samuel WEISBROD, Sebastian STARK, Tobias VOIGT
Estimating the term…
The present invention relates to a water-insoluble controlled-release pattern recognition receptor agonist (“PRRA”) or its pharmaceutically acceptable salt or a pharmaceutical composition comprising such water-insoluble controlled-release PRRA or its pharmaceutical acceptable salt for use in the treatment of a cell-proliferation disorder, wherein the water-insoluble controlled-release PRRA, its pharmaceutically acceptable salt or the pharmaceutical composition is administered by intra-tissue administration, and wherein at least 25% of the amount of PRRA remains local in such tissue 3 days after administration; and to related aspects.
A water-insoluble controlled-release pattern recognition receptor agonist (“PRRA”) for use in the treatment of a cell-proliferation disorder, wherein the water-insoluble controlled-release PRRA is administered by intra-tissue administration, and wherein at least 25% of the amount of PRRA remains local in such tissue 3 days after administration.
A water-insoluble controlled-release PRRA or the pharmaceutically acceptable salt thereof, wherein said water-insoluble controlled-release PRRA releases one or more PRRA and at least 25% of the amount of PRRA remains local in such tissue 3 days after intra-tissue administration.
Dependencies are inferred from the claim text.